Medistem announces initiation of critical limb ischemia study
No treatment-associated adverse events were observed in either of the patients in the study during the ERC dosing procedure, which involves a series of intramuscular injections in the
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The collaboration focuses on late-phase research, recruiting for and monitoring of clinical trials, and post-market surveillance. The partnership aims at developing products that overcome obstructions in clinical research,